Citigroup Inc Intellia Therapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 342,966 shares of NTLA stock, worth $7.68 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

342,966

Previous 167,606 104.63%

Holding current value

$7.68 Million

Previous $5.11 Million 84.62%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$23.82 - $32.8 $4.18 Million - $5.75 Million	175,360 Added 104.63%	342,966 $9.43 Million
Q4 2023 Feb 09, 2024	SELL	$23.16 - $32.34 $2.27 Million - $3.16 Million	-97,798 Reduced 36.85%	167,606 $5.11 Million
Q3 2023 Nov 09, 2023	BUY	$31.62 - $45.78 $2.98 Million - $4.32 Million	94,363 Added 55.17%	265,404 $8.39 Million
Q2 2023 Aug 10, 2023	BUY	$34.58 - $46.03 $517,074 - $688,286	14,953 Added 9.58%	171,041 $6.98 Million
Q1 2023 May 11, 2023	BUY	$33.3 - $44.82 $1.9 Million - $2.55 Million	56,967 Added 57.47%	156,088 $5.82 Million

Q4 2022 Feb 09, 2023	SELL	$33.21 - $62.69 $587,186 - $1.11 Million	-17,681 Reduced 15.14%	99,121 $3.46 Million
Q3 2022 Nov 10, 2022	BUY	$53.92 - $71.7 $825,353 - $1.1 Million	15,307 Added 15.08%	116,802 $6.54 Million
Q2 2022 Aug 10, 2022	SELL	$38.49 - $76.21 $9.13 Million - $18.1 Million	-237,291 Reduced 70.04%	101,495 $5.25 Million
Q1 2022 May 12, 2022	BUY	$58.27 - $118.99 $15.9 Million - $32.5 Million	273,107 Added 415.82%	338,786 $24.6 Million
Q4 2021 Feb 10, 2022	SELL	$100.76 - $138.36 $642,143 - $881,768	-6,373 Reduced 8.85%	65,679 $7.77 Million
Q3 2021 Nov 10, 2021	BUY	$132.37 - $176.78 $9.54 Million - $12.7 Million	72,052 New	72,052 $9.67 Million

Others Institutions Holding NTLA

# of Institutions

313

Shares Held

89.3M

Call Options Held

686K

Put Options Held

599K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.7B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account